SCHEMBL4833245

SCHEMBL4833245

Brc1c[c]c(OCc2ccccc2OCc2ccc(OCc3ccccc3)c(OCc3ccccc3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 3/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
CCR5 P51681 4/20 0.43
ALDH1A1 P00352 3/20 0.42
USP28 Q96RU2 1/20 0.42
USP25 Q9UHP3 1/20 0.42
RAB9A P51151 1/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTT P42858 3/20 0.41
SLC6A4 P31645 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPY1R P25929 1/20 0.40
NPY2R P49146 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGER1 P34995 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609423 0.81 MAOB (0.46) CCR5ALDH1A1USP28USP25RAB9A
SCHEMBL4833255 0.78 ABCB1 (0.45) ABCB1ABCG2CCR5ALDH1A1USP28
SCHEMBL31644088 0.72 SLC6A4 (0.66) CCR5ALDH1A1USP28USP25RAB9A
SCHEMBL368071 0.72 SLC6A4 (0.66) CCR5ALDH1A1USP28USP25RAB9A
SCHEMBL2578952 0.70 DRD2 (0.57) ABCB1CCR5ALDH1A1USP28USP25
SCHEMBL28402660 0.69 RAB9A (0.43) CCR5RAB9AHTR1ADRD2SLC6A4
SCHEMBL3236287 0.68 SLC2A1 (0.52) ALDH1A1RAB9ASLC6A4KDM4EKMT2A
SCHEMBL15196646 0.67 CCR5 (0.63) CCR5ALDH1A1USP28USP25RAB9A
SCHEMBL561347 0.67 CCR5 (0.68) CCR5ALDH1A1USP28USP25RAB9A
SCHEMBL30353418 0.67 CCR5 (0.68) CCR5ALDH1A1USP28USP25RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US claimed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US claimed
WO-2005014534-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO claimed
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US disclosed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US disclosed
WO-2005014534-A1 ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRANSTECH PHARMA, INC. (US) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use CYP2F1, CYP3A43, PNPO ABCB1 351/4885ABCG2 113/4885CCR5 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.